Guardant Health pulls in sizable Series B for next-gen sequencing Dx; Foundation Medicine abandons plans to raise $150M;

> Guardant Health, a gene-sequencing-based diagnostics firm, has finished what has now become a $30 million Series B financing, in a round led by Khosla Ventures that also included Sequoia Capital and new investor Pejman Mar Ventures. Story (sub. req.)

> Diagnostics luminary Foundation Medicine ($FMI) has abandoned plans to raise $150 million in a secondary offering in the wake of a bearish market. Story

> Quest Diagnostics ($DGX) has completed its acquisition of prevention and wellness services outfit Summit Health. Story

> Boston Heart Diagnostics in Massachusetts has obtained its New York laboratory permit for diagnostic testing. The company produces next-generation tests for cardiovascular disease. Release

> Researchers found that a particular biomarker helped identify patients who might respond best to a specific melanoma treatment. Story

> North Carolina's Zenalux Biomedical will work with the Buffalo, NY-based Roswell Park Cancer Institute to enhance one of its devices for improved oral cancer detection. Release

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.